Literature DB >> 23079641

Inhibitory activities and possible anticancer targets of Ru(II)-based complexes using computational docking method.

Adebayo A Adeniyi1, Peter A Ajibade.   

Abstract

In an effort to search for better alternatives to cis-platin and its derivatives that are non-selective cytotoxic anticancer agents, many metal based complexes especially that of Ru(II) that will have alternate targets other than universal target such as DNA have been suggested. This paper focus more on finding an alternative protein targets other DNA for some Ru(II)-based complexes using computational docking as a means of addressing commonly reported research challenges with regards to the lack of proper understanding of the anticancer targets of Ru-based complexes. The observed interactions through our docking studies showed that, besides predicted targets such as CatB, HP-NCP and kinase which is in good agreement with experiment since they have been experimentally suggested as possible target of Ru-based anticancer agents, other targets such as RNR and HDAC7 are proposed. Majority of the complexes on the average showed good interactions with rHA which will most likely enhance their pharmacokinetic properties. There is the possibility of some of them acting as anticancer and as antibacterial agent because they bind more favourably with DNA-Gyrase.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079641     DOI: 10.1016/j.jmgm.2012.08.004

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  2 in total

1.  Comparing the suitability of autodock, gold and glide for the docking and predicting the possible targets of Ru(II)-based complexes as anticancer agents.

Authors:  Adebayo A Adeniyi; Peter A Ajibade
Journal:  Molecules       Date:  2013-03-25       Impact factor: 4.411

2.  Bioactive Salen-type Schiff Base Transition Metal Complexes as Possible Anticancer Agents.

Authors:  Maryam Damercheli; Mahdi Mahdi; Bita Mehravi; Mehdi Shafiee Ardestani
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.